Change Language:
The study, funded through the European Fair Price Network (EFPN), assessed the time to patient access at hospital level, adding that products first entered the market through early access programs. A total of six cutting-edge cancer drugs in 20 indications were considered as in this study, adding Tagrisso (osimertinib) from AstraZeneca (UK), Yervoy (ipilimumab) and Opdivo (nivolumab) from Bristol Myers Squibb (BMS, USA). USA), Johnson and Johnson.
In the study published by the National Library of Medicine, the longest periods between positive EMA opinion and treatment were recorded in Hungary and Belgium, followed by Switzerland and the Netherlands.
The expansion of early national programs is one of many points that would potentially influence the faster arrival of oncology drugs by patients in the countries evaluated. Pricing flexibility, the respective countries’ charge containment policies, and the P systems
In the Netherlands, the P system
The points at which patients’ access to those markets are very similar to a country’s pricing procedure and the eligibility criteria implemented for reimbursement. The stricter criteria implemented in the Netherlands have potentially caused this delay in patient access to new oncology drugs compared to other EU countries. and, consequently, delay prices and expected repayment timelines, put downward pressure on costs, and put the country later in the release order. While the Netherlands runs an early access program through the Access to Medicines Protocol, there are too strict eligibility criteria, while countries with more flexible pricing procedure in the form of national early access programs, such as France, have seen a significant improvement in market access.
Your email will arrive shortly
Check out all the newsletters of the GlobalData Media network.